ReviewAmerican journal of translational research2021
Mechanisms of COVID-19 thrombosis in an inflammatory environment and new anticoagulant targets.
Review in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Thoracolumbar spine surgery in the post-pandemic era: a national retrospective analysis of thrombotic complications, vaccination status, and prior hospitalization with COVID-19.Asian spine journal · 2026Article
- New-onset adrenal insufficiency in COVID-19 patients without preexisting adrenal disease: A systematic review.Qatar medical journal · 2026Review
- Uncovering common pathways and potential drug targets in COVID-19 and venous thrombosisCentral-European journal of immunology · 2026Article
- Spontaneous Retroperitoneal Hematoma in SARS-CoV-2 Patients: Diagnostic and Management Challenges-A Literature Review.Journal of clinical medicine · 2025Review
- Risk of pulmonary embolism and deep vein thrombosis following COVID-19: a nationwide cohort study.MedComm · 2024Article
- Estimated plasma volume status in COVID-19 patients and its relation to comorbidities and clinical outcomes.Journal of thrombosis and thrombolysis · 2024Article
- Placental pathology in sudden intrauterine death (SIUD) in SARS-CoV-2-positive oligosymptomatic women.Archives of gynecology and obstetrics · 2023Article
- Dysregulated haemostasis in thrombo-inflammatory disease.Clinical science (London, England : 1979) · 2022Review
- Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients.Journal of clinical medicine · 2022Article
- The role of electrolyte imbalances in predicting the severity of COVID-19 in the hospitalized patients: a cross-sectional study.Scientific reports · 2022Article
- SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection.Clinical science (London, England : 1979) · 2022Article
- The FCGR2A rs1801274 polymorphism was associated with the risk of death among COVID-19 patients.Clinical immunology (Orlando, Fla.) · 2022Article
- Factors Determining Plasticity of Responses to Drugs.International journal of molecular sciences · 2022Review
- Circulating Microparticles in the Pathogenesis and Early Anticoagulation of Thrombosis in COVID-19 With Kidney Injury.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is widely epidemic in the world and poses a great threat to our life. Coagulopathy is one of the major characteristics in the COVID-19 patients. A growing number of studies have found that the severe COVID-19 patients have thrombotic microangiopathy and thromboembolism. Coagulopathy associated with increased risk of death in the patients. Unfortunately, the mechanism of coagulopathy is not clearly addressed. Understanding the pathophysiological mechanism of COVID-19 thrombosis and improving the coagulopathy through efficient treatment may help to stop disease progression, reduce mortality and sequelae. In severe COVID-19 patients, inflammation, cytokine storm, and coagulation are closely related, which together cause blood congestion and thrombosis. Many cytokines activate blood cells, expressing activating factors or releasing activated microparticles, and then accelerating thrombosis. However, the role of blood cells is not well understood in COVID-19 patients. In addition, cytokines stimulate endothelial cells, transforming them into a procoagulant phenotype. Therefore, determine their role and propose new strategies for the prevention and treatment of thrombosis in severe COVID-19 patients. We outline the major events of coagulopathies, discuss the role of blood and endothelial cells in thrombosis, to formulate a new anticoagulation protocol.
Indexed as
Identifiers
34149990PMC8205677W3168133069What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.